The seville expert workshop for progress in posttransplant lymphoproliferative disorders

Transplantation

Volumn 94, Issue 8, 2012, Pages 784-793

  Glotz, Denis ^a   Chapman, Jeremy R ^b   Dharnidharka, Vikas R ^c   Hanto, Douglas W ^d   Castro, Maria C R ^e   Hirsch, Hans H ^f   Leblond, Véronique ^g   Mehta, Aneesh K ^h   Moulin, Bruno ⁱ   Pagliuca, Antonio ^j   Pascual, Julio ^k   Rickinson, Alan B ^l   Russo, Francesco P ^m   Trappe, Ralf U ⁿ   Webster, Angela C ^b   Zuckermann, Andreas O ^o   Gross, Thomas G ^p  

^a SAINT LOUIS HOSPITAL   (France)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF FLORIDA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

^k HOSPITAL DEL MAR   (Spain)

^l UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^m UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p NATIONWIDE CHILDREN S HOSPITAL   (United States)

more..

Author keywords

Epstein Barr virus infection; Immunosuppression; Lymphoproliferative disorder; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; EPSTEIN BARR VIRUS VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY CD3; PLACEBO; RITUXIMAB; THYMOCYTE ANTIBODY;

CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; EPSTEIN BARR VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAINTENANCE THERAPY; MEDICAL EDUCATION; MEDICAL EXPERT; MEDICAL RESEARCH; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROGNOSIS; RETREATMENT; REVIEW; RISK FACTOR; RISK REDUCTION; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; RISK FACTORS; VIRAL LOAD;

EID: 84868191304     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318269e64f     Document Type: Review

References (85)

1. Dharnidharka V, Green M, Webber SA, eds. Post-Transplant Lymphoproliferative Disorders. 1st ed. Berlin, Germany: Springer; 2009.
2. Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, et al. Posttransplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 2010; 25: 2089.
3. Allen U, Alfieri C, Preiksaitis J, et al. Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis 2002; 13: 89.
4. Allen U, Preiksaitis J. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant Recipients. Am J Transplant 2009; 9: S87.
5. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346.
6. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell posttransplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196.
7. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meetingYAirlie House, Virginia, November, 1997. Hematol J 2000; 1: 53.
8. Swerdlow SH, Webber SA, Chadburn A, et al. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe NL, Pileri SA, Stein H, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:343Y349.
9. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8.
10. Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010; 149:693.
11. Zimmermann H, Oschlies I, Fink S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German posttransplant lymphoproliferative disorder registry. Transplantation 2012; 93: 543.
12. Zimmermann H, Reinke P, Neuhaus R, et al. Burkitt post-transplant lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab followed by CHOP or RCHOP is safe and effective in an analysis of eight cases. Cancer 2012; 118: 4639.
13. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like posttransplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica 2011; 96: 1067.
14. Oertel SH, Anagnostopoulos I, Hummel MW, et al. Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 2002; 118: 1120.
15. Trappe R, Riess H, Anagnostopoulos I, et al. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone. Ann Hematol 2009; 88: 167.
16. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052.
17. Shimoyama Y, Asano N, KojimaM, et al. Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity. Pathol Int 2009; 59: 835.
18. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630.
19. Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86: 599.
20. Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant 2006; 6: 2735.
21. Evens AM, Choquet S, Smith SM, et al. Primary central nervous system (PCNS) post-transplant lymphoproliferative disease (PTLD): an International report of 65 cases in the modern era. Blood 2011; 118: 879, Abstract 879.
22. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987.
23. Bustami RT, Akinlolu OO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87.
24. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
25. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival afterprimary kidney transplantation. Transplantation 2003; 76:1289.
26. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065.
27. Dharnidharka VR, Tejani AH, Ho P-L, et al. Post-transplant lymphoproliferative disorder in the United States: young, Caucasian males are at highest risk. Am J Transplant 2002; 2: 993.
28. Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005; 9: 622.
29. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005; 80: 193.
30. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant proliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894.
31. Herzig KA, Juffs HG, Norris D, et al. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int 2003; 16: 529.
32. Issa N, Amer H, Dean PG, et al. Posttransplant lymphoproliferative disorder following pancreas transplantation. Am J Transplant 2009; 9: 1894.
33. Johnson SR, Cherikh WS, Kauffman HM, et al. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 2006; 6: 2743.
34. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619.
35. Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6: 1017.
36. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370.
37. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
38. Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227.
39. Opelz G, Daniel V, Naujokat C, et al. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962.
40. Opelz G, Dohler B. Impact of HLA mismatching on incidence of posttransplant non-Hodgkin lymphoma after kidney transplantation. Transplantation 2010; 90: 292.
41. Pourfarziani V, Einollahi B, Taheri S, et al. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant 2007; 12: 16.
42. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, et al. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 2009; 13: 54.
43. Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851.
44. Smith JM, Rudser K, Gillen D, et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation 2006; 81: 175.
45. Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 2006; 82: 1100.
46. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
47. van Leeuwen MT, Grulich AE, Webster AC, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114: 630.
48. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214.
49. van Leeuwen MT, Webster AC, McCredie MRE, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. Br Med J 2010; 340: c570.
50. Wong JY, Tait B, Levvey B, et al. Epsetin-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation 2004; 78: 205.
51. Wu JF, Ho MC, Ni YH, et al. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children. Transplantation 2009; 87: 758.
52. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009; 24: 731.
53. Morgans AK, Reshef R, Tsai DE. Posttransplant lymphoproliferative disorder following kidney transplant. Am J Kidney Dis 2010; 55: 168.
54. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 2004; 4(Suppl 10): 59.
55. Dharnidharka V, Gupta S. Viral immune monitoring for posttransplant lymphoproliferative disorder. Pediatr Transplant 2009; 13: 521.
56. Preiksaitis JK, Pang XL, Fox JD, et al. Interlaboratory comparison of epstein-barr virus viral load assays. Am J Transplant 2009; 9: 249.
57. Green M, Soltys K, Rowe DT, et al. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2009; 13: 319.
58. Jang JY, Kim KM, Lee YJ, et al. Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation. Transplant Proc 2008; 40: 2546.
59. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222.
60. Choquet S, Varnous S, Deback C, et al. Adapted management of EBV reactivation after solid organ transplantation: an effective prevention of post transplantation lymphoproliferative disorders (PTLD). Results of the largest prospective study on 251 patients. Blood 2010; 261: 592; Abstract 592.
61. Gajarski RJ, Blume ED, Urschel S, et al. Infection and malignancy after pediatric heart transplantation: The role of induction therapy. J Heart Lung Transplant 2011; 30: 299.
62. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521.
63. Lanza LL, Wang L, Simon TA, et al. Epidemiologic critique of literature on post-transplant neoplasms in solid organ transplantation. Clin Transplant 2009; 23: 582.
64. Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008; 359: 1736.
65. Varagunam M, Yaqoob MM, Dohler B, et al. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med 2009; 360: 874.
66. Darenkov IA,MarcarelliMA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848.
67. Malouf MA, Chhajed PN, Hopkins P, et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21: 547.
68. Manlhiot C, Pollock-Barziv SM, Holmes C, et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant 2010; 29: 648.
69. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.
70. Green M, Kaufmann M, Wilson J, et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997; 25: 1344.
71. Green M, MichaelsMG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906.
72. Humar A, Hebert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81: 856.
73. Opelz G, Daniel V, Naujokat C, et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007; 8: 212.
74. Danziger-Isakov L, Mark BG. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant 2009; 23: 295.
75. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675.
76. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010; 23: 350.
77. Kidney Disease: Improving Global Outcomes (KDIGO)Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): S1.
78. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108.
79. Turner AP, Shaffer VO, Araki K, et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011; 11: 613.
80. Pascual J. Post-transplant lymphoproliferative disorderYthe potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22(Suppl 1): i27.
81. Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104: 1661.
82. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053.
83. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038.
84. Svoboda J, Kotloff R, Tsai DE. Management of patients with posttransplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006; 19: 259.
85. Macedo C, Zeevi A, Bentlejewski C, et al. The impact of EBV load on T-cell immunity in pediatric thoracic transplant recipients. Transplantation 2009; 88: 123.